4-(trifluoromethyl)-1H-indole

We are 4-(trifluoromethyl)-1H-indole CAS:128562-95-8 manufacturer and supplier in China, Pls send inquiry of to info@nbinno.com of visit www.nbinno.com our official website should you have any interests

Chemical Name:4-(trifluoromethyl)-1H-indole
CAS.NO:128562-95-8
Synonyms:4-(trifluoromethyl)-1H-indole
 
Physical and Chemical Properties:
Density 1.4±0.1 g/cm3
Boiling Point 256.7±35.0 °C at 760 mmHg
Molecular Formula C9H6F3N
Molecular Weight 185.146
Flash Point 109.0±25.9 °C
Vapour Pressure 0.0±0.5 mmHg at 25°C
Index of Refraction 1.556
 
Specification:
Appearance:White to light yellow crystalline powder
Assay:≥97.0%
 
Packing:25 kg/drum, can also be packaged according to customer requirements
Storage:Store in a cool, ventilated place
Application:Intermediate of Organic synthesis.

4-(trifluoromethyl)-1H-indole


Related News: Zhejiang Huahai Pharmaceutical: It is a leading company in domestic APIs, especially in the field of cardiovascular drugs.4-Cloromethyl-5-methyl-1,3-dioxol-2-one CAS:80841-78-7 Zhejiang Huahai Pharmaceutical: It is a leading company in domestic APIs, especially in the field of cardiovascular drugs.N-(biphenyl-4-yl)-3-carbazoleboronic acid CAS:1028648-22-7 In recent years, the government has heavily promoted TCM, as part of efforts by Xi to bolster the country’s health sector and fill the gaps in national insurance schemes.3-Chloro-5-(trifluoromethyl)picolinic acid This dosage form may also support combination therapy modalities.? To date, over 400 patients have been dosed with the oral formulation of rigosertib in clinical trials.? Combination therapy of oral rigosertib with azacitidine, the standard of care in HR-MDS, has also been studied. Currently, oral rigosertib is being developed as a combination therapy together with azacitidine for patients with higher-risk MDS who require HMA therapy.?This dosage form may also support combination therapy modalities.? To date, over 400 patients have been dosed with the oral formulation of rigosertib in clinical trials.? Combination therapy of oral rigosertib with azacitidine, the standard of care in HR-MDS, has also been studied. Currently, oral rigosertib is being developed as a combination therapy together with azacitidine for patients with higher-risk MDS who require HMA therapy.?

Related Products
Product Name
5-Nitrovanillin View Details
2,4-Dichloro-3-aminophenol hydrochloride View Details
Isobutyryl chloride View Details
1-(biphenyl-4-yl)-2-methyl-2-morpholinopropan-1-one manufacturer Ethyl 3,4-dihydroxybenzoate manufacturer phloroglucinol manufacturer (R)-(-)-Glycidyl phthalimide manufacturer 5-Bromo-2-fluoroaniline manufacturer